Clinical trial · Interventional
Photodynamic Therapy With HPPH in Treating Patients With Non-Small Cell Lung Cancer
A Phase I Study of Photodynamic Therapy (PDT) Using 2-(1-hexyloxyethyl)-2 Devinyl Pyropheophorbide-a (HPPH) for Treatment of Early Stage Lung Cancer - A Dose Ranging Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Photodynamic therapy uses light and drugs that make tumor cells more sensitive to light to kill tumor cells. Photosensitizing drugs such as HPPH are absorbed by tumor cells and, when exposed to light, become active and kill the tumor cells. PURPOSE: Phase I trial to study the effectiveness of photodynamic therapy with HPPH in treating patients who have non-small cell lung cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| HPPH | Drug | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Histologically confirmed microinvasive or centrally obstructing non-small cell lung cancer * Squamous cell carcinoma * Adenocarcinoma * Large cell carcinoma PATIENT CHARACTERISTICS: Age: * 18 and over Performance status: * Karnofsky 50-100% OR * ECOG 0-2 Life expectancy: * Not specified Hematopoietic: * WBC at least 2,000/mm\^3 * Platelet count at least 50,000/mm\^3 Hepatic: * Bilirubin no greater than 3.0 mg/dL * Alkaline phosphatase no greater than 3 times upper limit of normal (ULN) * SGOT no greater than 3 times ULN * PT no greater than 1.5 times ULN Renal: * Creatinine no greater than 3.0 mg/dL Pulmonary: * No severe chronic obstructive pulmonary disease that would preclude study Other: * Not pregnant * Fertile patients must use effective contraception * No contraindications to bronchoscopy * No porphyria * No hypersensitivity to porphyrin or porphyrin-like compounds PRIOR CONCURRENT THERAPY: Biologic therapy: * Prior biologic therapy for lung cancer allowed Chemotherapy: * At least 4 weeks since prior chemotherapy * No concurrent chemotherapy Endocrine therapy: * Prior endocrine therapy for lung cancer allowed Radiotherapy: * At least 4 weeks since prior radiotherapy * No concurrent external beam radiotherapy Surgery: * No concurrent surgery Other: * Prior therapy for lung cancer allowed
References
Publications (0)
Data not yet available